No clinical development in stroke . Action Thrombolytic agent . In stroke clinical trials, intravenous streptokinase increased stroke mortality or morbidity in several studies. No further development in stroke. .
Source Published reports. . .
The influence of baseline prognostic variables on outcome after thrombolysis. MAST-Italy Collaborative Group. Australian Streptokinase Trial Study Group. MAST-I Collaborative Group. Trial Study Group.